Cabozantinib vs. osimertinib: an in-depth comparison of two anticancer drugs

Cabozantinib and Osimertinib are two highly anticipated anti-cancer drugs in contemporary medicine. Although they are both designed to fight cancer, they show obvious differences in their mechanisms of action, treatment areas and possible side effects.

Cabozantinib, known as the leader of multi-target tyrosine kinase inhibitors, has shown remarkable results in the fight against various cancers, especially against advanced renal cell carcinoma, thyroid cancer and hepatocellular carcinoma. Its mechanism of action is mainly to block the proliferation and migration of cancer cells by inhibiting multiple key signaling pathways such as MET, VEGFR, and RET. What’s more worth mentioning is that cabozantinib can also effectively control the progression of bone metastasis, bringing hope of life to many patients.

However, the powerful effects of the drug may also be accompanied by a series of adverse reactions, such as diarrhea, fatigue, nausea, etc., which may even lead to high blood pressure and weakness. Therefore, it needs to be used under the guidance of a professional doctor and pay close attention to your physical condition.

Unlike cabozantinib, osimertinib is a highly selective and highly selective EGFR mutant inhibitor, especially for lung cancer patients with EGFR gene mutations. It has shown remarkable efficacy in first-line treatment, especially for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). In addition, for patients whose disease progresses after treatment with other EGFR tyrosine kinase inhibitors, Tagrisso can also exert excellent efficacy if testing confirms the presence of the EGFRT790M mutation.

But just like other drugs, Tagrisso may also cause some side effects, such as nausea, vomiting, diarrhea, etc. Although these reactions may affect the patient's quality of life, with regular monitoring and prompt treatment by doctors, most patients can continue treatment safely.